PMS38 COST-EFFECTIVENESS OF RITUXIMAB VERSUS ALTERNATIVE ANTI-TUMOR NECROSIS FACTOR (TNF) THERAPY AFTER PREVIOUS FAILURE OF ONE ANTI-TNF AGENT FOR TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO
Abstract
Authors
F Carlos
F Carlos
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now